

**Amendments to the Claims:**

**This listing of claims will replace all prior versions and listing of claims in the application.**

**Listing of the Claims:**

Claim 1 (original): An immediate release pharmaceutical composition comprising:

- (i) 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline or a pharmaceutically-acceptable salt thereof (the Agent);
- (ii) a water-soluble acid; and
- (iii) a water-soluble cellulose ether or an ester of a water-soluble cellulose ether.

Claim 2 (currently amended): The A-pharmaceutical composition according to claim 1 wherein  
(iii) is comprising the Agent, a water-soluble acid and a water-soluble cellulose ether.

Claim 3 (currently amended): The A-pharmaceutical composition according to claim 1 wherein  
(iii) is comprising the Agent, a water-soluble acid and an ester of a water-soluble cellulose ether.

Claim 4 (currently amended): The A-pharmaceutical composition according to claim 1 or claim  
2 wherein the comprising the Agent, a water-soluble acid and a water-soluble cellulose ether is  
selected from methyl cellulose, hydroxyethylcellulose, hydroxypropylcellulose and  
hydroxypropyl methylcellulose.

Claim 5 (currently amended): The A-pharmaceutical composition according to claim 1 or claim  
2 wherein the water-soluble cellulose ether is comprising the Agent, a water-soluble acid and  
methyl cellulose.

Claim 6 (currently amended): The A-pharmaceutical composition according to claim 1 or claim  
2 wherein the water-soluble cellulose ether is comprising the Agent, a water-soluble acid and

hydroxypropyl methylcellulose.

Claim 7 (currently amended): The A-pharmaceutical composition according to claim 1 or claim 3 wherein the ester of a water-soluble cellulose ether is the ~~comprising the Agent, a water-soluble acid and an ester of hydroxypropyl methylcellulose or the an ester of hydroxypropylcellulose wherein the ester is selected from which carries one or more of ester groups selected from acetate, succinate, phthalate, isophthalate, terephthalate and trimellitate.~~

Claim 8 (currently amended): The A-pharmaceutical composition according to claim 1 wherein the ~~or claim 2 comprising the Agent, a water-soluble acid and a water-soluble cellulose ether or the ester of a water-soluble cellulose ether is selected from hydroxypropyl methylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose and hydroxypropyl methylcellulose acetate succinate.~~

Claim 9 (currently amended): The A-pharmaceutical composition according to claim 1 ~~any one of the preceding claims wherein the water-soluble acid is solid at ambient temperature.~~

Claim 10 (currently amended): The A-pharmaceutical composition according to claim 1 ~~any one of the preceding claims wherein the water-soluble acid is a water-soluble aliphatic mono or polycarboxylic acid which may be saturated or unsaturated.~~

Claim 11 (currently amended): The A-pharmaceutical composition according to claim 10 ~~wherein the water-soluble acid is selected from fumaric acid and malic acid.~~

Claim 12 (currently amended): The A-pharmaceutical composition according to claim 1 ~~any one of the preceding claims wherein the molar ratio of Agent to acid is from 1:1 to 1:10.~~

Claim 13 (currently amended): The A-pharmaceutical composition according to claim 1 ~~any one of the preceding claims wherein the weight ratio of Agent to water-soluble cellulose ether, or~~

ester of water-soluble cellulose ether is from 30:1 to 3:1.

Claim 14 (currently amended): The A-pharmaceutical composition according to claim 1 comprising:

- (i) from 10 to 60 parts of the Agent;
  - (ii) from 2 to 70 parts of a water-soluble cellulose ether selected from methyl cellulose and hydroxypropyl methylcellulose; and
  - (iii) from 10 to 70 parts of a water-soluble organic acid selected from fumaric acid and malic acid;
- wherein all parts are by weight and the sum of the parts (i)+(ii)+(iii)=100; and wherein the molar ratio of Agent to organic acid is from 1:3 to 1:6.

Claim 15 (currently amended): The A-pharmaceutical composition according to claim 1 wherein any one of the preceding claims which comprises a physical mixture of the Agent, the water-soluble acid, and the water-soluble cellulose ether and/or ester of a water-soluble cellulose ether are a physical mixture.

Claim 16 (currently amended): The A-pharmaceutical composition according to claim 15 which is in the form of an oral immediate release tablet, pellet, granule or capsule formulation.

Claim 17 (withdrawn and currently amended): A method for reducing inter-patient and/or intra-patient variability in bioavailability and/or plasma concentrations of the Agent in a patient in need of the Agent comprising orally administering to said patient a pharmaceutical composition according to claim 1 ~~any one of claims 1 to 16~~, wherein the Agent is as defined in claim 1.

Claim 18 (withdrawn and currently amended): A method for increasing the solubilisation of the Agent in an aqueous medium with a pH value similar to those found in the upper GI tract of a human comprising adding to said aqueous medium a pharmaceutical composition according to claim 1 ~~any one of claims 1 to 16~~; wherein the solubilisation of the Agent from the composition

is increased compared to the solubilisation of the Agent alone in the same aqueous medium; and  
~~wherein the Agent is as defined in claim 1.~~

Claim 19 (withdrawn and currently amended): A method for inhibiting the rate of precipitation of the Agent from an aqueous solution comprising adding to an aqueous medium with a pH similar to the gastric pH in a human, a pharmaceutical composition according to claim 1 ~~any one of claims 1 to 16; wherein the Agent is as defined in claim 1.~~